Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2020-11-27 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司股份关于2020年限制性股票激励计划权益授予的进展公告
Share Issue/Capital Change Classification · 95% confidence The document is a progress announcement regarding the 2020 restricted stock incentive plan equity grant by the company. It details the completion of subscription by incentive recipients, the number of shares involved, and changes in share classification. It references a prior announcement and a verification report by an accounting firm. The document is relatively short (1084 characters) and serves as an update on the stock incentive plan progress rather than a full financial report or detailed management discussion. It is not an annual or interim report, nor a call transcript or earnings release. It is an announcement related to share capital changes specifically about restricted stock grants and share classification changes. Therefore, it fits best under Share Issue/Capital Change (SHA).
2020-11-27 Chinese
金宇生物技术股份有限公司关于变更持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of continuous supervision sponsors (保荐代表人) for a company's non-public stock issuance project. It details the replacement of individuals responsible for ongoing supervision duties related to the company's fundraising activities. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a regulatory announcement about management of sponsorship and supervision duties related to capital raising. This fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2020-11-20 Chinese
金宇生物技术股份有限公司监事会关于公司调整2020年限制性股票激励计划首次授予激励对象名单、授予数量及首次授予相关事项的核查意见
Share Issue/Capital Change Classification · 95% confidence The document is a supervisory board opinion on adjustments to the initial grant list and quantities of a 2020 restricted stock incentive plan. It discusses legal compliance, authorization by the shareholders' meeting, and details about the stock grant. This is related to share-based compensation and equity incentive plans, which typically fall under announcements about share issues or capital changes. The document is short (990 characters) and contains substantive content about the adjustment of share grants, not just an announcement of a report. Therefore, it is best classified as a Share Issue/Capital Change (SHA) filing.
2020-10-28 Chinese
金宇生物技术股份有限公司2020年限制性股票激励计划首次授予激励对象名单（调整后）
Share Issue/Capital Change Classification · 95% confidence The document is a detailed list of recipients of a restricted stock incentive plan, including allocation amounts and names of core management and technical personnel. It focuses on stock incentive distribution and personnel involved, without financial statements, earnings data, or regulatory certifications. It is not an annual report, earnings release, or management discussion. It is also not a voting result, board change, or financing update. The content aligns with disclosures related to share-based compensation plans, which typically fall under announcements of share issue or capital changes. Therefore, the document is best classified as a Share Issue/Capital Change (SHA) filing.
2020-10-28 Chinese
金宇生物技术股份有限公司关于向激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial grant of restricted shares (stock incentives) to certain employees and executives of the company. It details the number of shares granted, the grant price, the approval process, legal opinions, and the impact on financials. The content focuses on the company's stock incentive plan and its implementation rather than financial results, management changes, or regulatory filings. It is not a full financial report, earnings release, or management discussion. It is a formal announcement about a capital-related event (granting restricted stock), which fits best under Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about the stock grant, not just a brief notice or link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the classification is CAP with high confidence.
2020-10-28 Chinese
金宇生物技术股份有限公司关于调整2020年限制性股票激励计划首次授予激励对象名单和授予数量的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding adjustments to the list of recipients and quantities for a 2020 restricted stock incentive plan. It details board and supervisory meetings, legal opinions, and the approval process for the stock incentive adjustments. The content focuses on changes to stock incentive allocations and related governance procedures, not on financial results, earnings, or annual reporting. It is not a full financial report, earnings release, or management discussion. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement about changes in stock incentive plans, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Remuneration Information or Share Issue/Capital Change exactly, since it is about incentive plan adjustments rather than new share issuance or executive compensation disclosures. The document length is under 5,000 characters and is a detailed announcement, not a brief report publication notice.
2020-10-28 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.